BANAN (cefpodoxime proxetil) by Daiichi Sankyo is clinical pharmacology absorption and excretion: cefpodoxime proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime. Approved for development of drug-resistant bacteria, maintain the effectiveness of cefpodoxime proxetil, other antibacterial drugs and 3 more indications. First approved in 1992.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
BANAN is a brand of cefpodoxime proxetil, an oral third-generation cephalosporin antibiotic approved in 1992. It is a prodrug absorbed from the GI tract and de-esterified to active cefpodoxime, used to treat bacterial infections caused by susceptible organisms. The drug demonstrates good tissue penetration, including skin blister fluid and tonsillar tissue, with approximately 50% systemic bioavailability and minimal in vivo metabolism.
As a mature, LOE-approaching oral antibiotic with 30% competitive pressure, BANAN teams are likely focused on market defense and managed care negotiations rather than growth initiatives.
CLINICAL PHARMACOLOGY Absorption and Excretion: Cefpodoxime proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime. Following oral administration of 100 mg of cefpodoxime proxetil to fasting subjects, approximately 50% of the…
Worked on BANAN at Daiichi Sankyo? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients.
Coolsculpting With Cooltone Verses Coolsculpting Alone for the Banana Roll Area
Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
BANAN offers limited direct career growth due to zero linked job openings and LOE-approaching status; roles focus on margin protection and payer negotiation rather than expansion. Career value lies in managed care expertise, healthcare economics, and portfolio defense strategies in a mature oral antibiotic market dominated by Pfizer variants.